IMMUNOTHERAPY WITH NONDEPLETING ANTI-CD4 MONOCLONAL ANTIBODIES BUT NOT CD28 ANTAGONISTS PROTECTS ISLET GRAFT IN SPONTANEOUSLY DIABETIC NOD MICE FROM AUTOIMMUNE DESTRUCTION AND ALLOGENEIC AND XENOGENEIC GRAFT REJECTION1

Abstract

Nondepleting anti-CD4 mAbs but not CD28 antagonists protect islet grafts in diabetic NOD mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. The efficacy of nondepleting anti-CD4 mAbs is compromised when it combines with CTLA4Ig.